https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more
Version 10.1_5 October 2020
These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website.
The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ...table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases.
Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanese
more
The design of anaesthesia equipment for use in hospitals in the developing world must take intoaccount the local conditions, particularly whether reliable supplies of compressed oxygen andelectricity are available. Designs should ensure that maintenance is feasible locally. Internationalstandards sh...ould encourage the design of suitable equipment to ensure safe anaesthesia for patientsworldwide
Anaesthesia, 2007,62(Suppl. 1), pages 54–60
more
2006-2008 programme report
This progress report reviews recent gains, new developments and remaining challenges as countries approach the 2020 targets of the Start Free Stay Free AIDS Free framework.
Результаты исследования «Изучение распространенности коронавирусной инфекции COVID-19 среди инфицированных ВИЧ пациентов вРоссии ивлияния эпидемии коронавирусной... инфекции COVID-19 на оказание медицинской помощипри ВИЧ-инфекции»
This study shows the negative impact that the COVID-19 pandemic is having on access to HIV care in the Russian Federation and shows that people living with HIV in the country are more susceptible to COVID-19 but less likely to seek testing or treatment.
More than a third of people living with HIV who were surveyed reported some impact on HIV services, including about 4% who reported that they had missed taking antiretroviral therapy because they could not get the medicine and nearly 9% who reported that they had missed taking medicine for tuberculosis prevention. However, the majority of respondents (about 70% of people living with HIV) did not experience problems obtaining antiretroviral therapy and about 22% reported that antiretroviral medicines were delivered to their home. More than 900 respondents from 68 regions of the Russian Federation, including people living with HIV and those who are not, were reached by the study.
more
2021 UNAIDS Global AIDS Update. UNAIDS report shows that people living with HIV face a double jeopardy, HIV and COVID-19, while key populations and children continue to be left behind in access to HIV services
Editorial| Volume 2, ISSUE 9, e415, September 01, 2021
TB situation in vulnerable populations. Rev. Nac. (Itauguá) vol.13 no.1 Itauguá jun. 2021
La pandemia de covid-19 ha afectado la detección y tratamiento de pacientes con TBC en Paraguay que lejos de ser una enfermedad erradicada, es motivo de preocupación sanitaria y sigue afectando a miles de ...personas, si bien se inician actividades de campo con apoyo del PNCT para la búsqueda activa, seguimiento de casos y control de contactos en comunidades indígenas y asentamientos, estas tareas no son continuas debido al aumento de los casos de covid-19 en el país, que favorece el temor a acudir a los hospitales para el diagnóstico, a sus controles e incluso se ve afectado el retiro de los medicamentos. En el marco de la pandemia, es probable que aumenten los fracasos terapéuticos con el consiguiente desenlace fatal, por lo que debe hacerse una revisión de las estrategias dirigidas a poblaciones vulnerables con un compromiso verdadero del sector político, sumado a una fuerte colaboración multisectorial e intercultural para lograr el fin de la TBC
more
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida introdução e implementação do pDTG é uma priori...dade para implementar as diretrizes da Organização Mundial da Saúde (OMS) e garantir que as crianças que vivem com VIH recebam o melhor tratamento disponível da SIDA de primeira e segunda linha o mais rápido possível. É importante notar que uma única substituição pDTG deve ocorrer independentemente da disponibilidade de um teste/carga viral (CV), ou do valor do último resultado de CV, mantendo ou otimizando as crianças usando abacavir/lamivudina (ABC/3TC) como base. Atualmente, mais de 30 países têm planos de adoção e implementação do pDTG.
more
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA. This document has two aims: firstly, to outline what is known of the Ukrainian HIV epidemic, and secondly, to use the HIV continuum o...f care as a framework to set out suggestions based on published evidence and expert opinion on the management of the HIV continuum of care, with special consideration for people living with HIV from Ukraine. The document will also address the needs of those at risk of acquiring HIV. The main findings of this document were presented during an ECDC webinar, ‘Key considerations on the continuum of HIV care for refugees from Ukraine,’ hosted on 19 May 2022.
more
Phillips and colleagues have shown that rifampicin combined with clarithromycin is non-inferior to RS8, and is safer. This much anticipated trial provides us with a high degree of confidence that an 8-week course of oral rifampicin and clarithromycin should now be the cornerstone of the treatment of... Buruli ulcer everywhere. However, this finding does not mean that
Buruli ulcer is cured at 8 weeks.
more
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim...ited. Pathogenesis of the characteristic painless ulcers is linked to the elaboration by M. ulcerans of a lipid toxin called mycolactone that has potent cytopathic, immunosuppressive, and analgesic effects on a host of cells in cutaneous tissues. Mycolactone is known to profoundly inhibit secretion of a plethora of proteins that are essential for wound healing. Even though a combination antibacterial therapy of streptomycin and rifampicin for 8 weeks is effective for treatment, it relies on good and appropriate wound management to prevent secondary bacterial infections and improve healing. Evidence-based interventions for wound care in Buruli ulcer disease are often lacking and have relied on expert advice and recommendations. Surgical interventions are limited to debridement of necrotic tissue and grafting of extensive ulcers, usually after antibiotic therapy. Patients’ rehabilitation is an important component of care to reduce disabilities associated with the disease and proper integration into the community after treatment.
more
Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are... limited to antibiotics with severe side effects. Here, we show that M. ulcerans is susceptible to the anti-tubercular drug Q203 and related compounds targeting the respiratory cytochrome bc1:aa3. While the cytochrome bc1:aa3 is the primary terminal oxidase in Mycobacterium tuberculosis, the presence of an alternate bd-type terminal oxidase limits the bactericidal and sterilizing potency of Q203 against this bacterium. M. ulcerans strains found in Buruli ulcer patients from Africa and Australia lost all alternate terminal electron acceptors and rely exclusively on the cytochrome bc1:aa3 to respire. As a result, Q203 is bactericidal at low dose against M. ulcerans replicating in vitro and in mice, making the drug a promising candidate for Buruli ulcer treatment.
more
Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572
PLoS ONE 13(11): e0207554. https://doi.org/ 10.1371/journal.pone.020755